University of Chicago | GenomeWeb

University of Chicago

The system, developed in 2007 as an online portal to access hardware and software for automated metagenome analysis, has strained to meet user demand.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The newly minted company offers panel, whole-genome and whole exome sequencing, as well as bioinformatics analysis and reporting services to oncologists.

The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.

Clinicians and genetic counselors are coming up with triage strategies for cancer cases in which medically actionable germline mutations are suspected.

A comparative genomics study suggests ants with obligate mutualist relationships to plants may have higher rates of molecular evolution than generalist ants.

The agency said researchers from around the world will have the capacity to review and submit cancer patients' genomic and clinical data.

The researchers will use TwoXar's software to predict potential candidates for atherosclerosis drugs and test them in pre-clinical studies.

The research team found three novel polymorphisms on chromosome 20 associated with an increased risk of blood clots in populations of African descent.

The University of Chicago's Jason Lieb has resigned as a university investigation recommended his termination for violating its sexual misconduct policy, the New York Times reports.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.